Follicular lymphoma is diagnosed through a combination of lymph node biopsy, immunophenotyping, imaging scans, and blood tests. No single test confirms it on its own. The process typically starts when a doctor notices persistently swollen lymph nodes and removes one (or a large piece of one) to examine under a microscope, then layers on additional testing to confirm the subtype, grade, and stage.
Why a Biopsy Is the First Step
The cornerstone of diagnosing follicular lymphoma is an excisional biopsy, where a surgeon removes an entire lymph node or a large portion of one. This is considered the gold standard because pathologists need to see the overall architecture of the tissue, specifically the pattern of abnormal follicles (rounded clusters of cells) that give this lymphoma its name. A fine needle aspiration, which pulls out only a small number of loose cells, has a high false-negative rate and low specificity for blood cancers, making it unreliable for this purpose.
Core needle biopsy, which extracts a thin cylinder of tissue, can work as an alternative in some situations. But it has a known limitation: the smaller sample makes it harder to assess the full tissue pattern, which is particularly important for low-grade lymphomas like follicular lymphoma. When a core needle biopsy comes back inconclusive, an excisional biopsy is usually the next step.
What Pathologists Look for Under the Microscope
Once the lymph node is removed, a pathologist examines it for two key features: the growth pattern of abnormal follicles and the mix of cell types inside them. Follicular lymphoma cells are B cells (a type of immune cell) that cluster into follicle-like structures mimicking the germinal centers found in healthy lymph nodes.
Grading depends on counting the number of large, immature cells called centroblasts in the tissue. In grade 1 and 2 disease, most cells are small with only a few centroblasts scattered among them. Grade 3A has a noticeably higher number of centroblasts (more than 15 per high-power field) but still contains smaller cells. Grade 3B, now renamed “follicular large B-cell lymphoma” in the latest WHO classification, consists almost entirely of centroblasts with no smaller cells remaining. This grading matters because higher grades tend to behave more aggressively and may need different treatment.
Immunophenotyping: The Molecular Fingerprint
Microscopic appearance alone isn’t enough. Pathologists run a panel of specialized stains and flow cytometry tests to identify specific proteins on the surface of the lymphoma cells. This molecular fingerprint is what separates follicular lymphoma from other B-cell lymphomas that can look similar under the microscope.
The typical profile of follicular lymphoma cells is: positive for the B-cell markers CD19 and CD20, positive for CD10 (a germinal center marker found in 95% to 100% of grade 1 cases), and negative for CD5, CD23, and CD200. The cells also show restricted expression of one type of antibody light chain (either kappa or lambda, but not both), which signals they’re all clones of a single abnormal cell rather than a normal mix of immune cells.
These markers are critical for telling follicular lymphoma apart from lookalikes. Mantle cell lymphoma, for example, is typically positive for cyclin D1, which follicular lymphoma is not. Marginal zone lymphoma is usually negative for CD10 and BCL6 but may express a marker called MNDA that follicular lymphoma rarely shows. BCL2, a protein that helps cells resist normal programmed death, is overexpressed in most follicular lymphoma cases due to a characteristic genetic change, and staining for it adds another piece of confirmatory evidence.
The Genetic Hallmark
About 85% of follicular lymphoma cases carry a specific chromosomal rearrangement known as the t(14;18) translocation. This genetic swap places a survival gene (BCL2) next to a powerful promoter region, causing the lymphoma cells to produce excess BCL2 protein and resist dying when they normally would. Testing for this translocation through techniques like FISH (fluorescence in situ hybridization) or PCR helps confirm the diagnosis.
It’s worth knowing, though, that standard assays detect this translocation in only about half of cases because they typically look for breaks in one specific region of the gene. Other breakpoints exist that these tests may miss. So a negative result doesn’t rule out follicular lymphoma if the rest of the evidence points toward it. The translocation can also appear in other types of non-Hodgkin lymphoma, so it’s never interpreted in isolation.
Imaging: PET-CT vs. Standard CT
After the biopsy confirms follicular lymphoma, imaging scans map where the disease has spread. PET-CT, which combines metabolic imaging with anatomical scanning, is more accurate than standard CT for this purpose. Standard CT relies on lymph node size to identify disease, which means it can miss involved nodes that haven’t enlarged yet. PET-CT detects metabolic activity instead, picking up disease that a CT scan would overlook.
The difference is significant. In one study of 68 patients with non-Hodgkin lymphoma, PET-CT upstaged the disease (found it was more advanced than CT suggested) in 31% of cases and downstaged it in only 1%. This matters because accurate staging directly affects treatment decisions, particularly the choice between localized radiation and systemic therapy. PET-CT also establishes a baseline that doctors later compare against to evaluate how well treatment is working.
Blood Tests and Lab Work
Blood tests don’t diagnose follicular lymphoma directly, but they provide important information about how the disease is affecting your body and what your likely outlook is. A complete blood count checks for anemia or other abnormalities in blood cell production. Two blood markers carry particular prognostic weight: lactate dehydrogenase (LDH), an enzyme that rises when cells are breaking down rapidly, and beta-2 microglobulin, a protein shed by immune cells that reflects overall tumor burden.
Elevated beta-2 microglobulin is associated with more advanced disease, higher LDH, and worse outcomes. Its prognostic value is independent of other factors, with one study finding it carried a hazard ratio of 2.9 for overall survival even after accounting for other risk indicators. Beta-2 microglobulin was eventually incorporated into the updated FLIPI-2 prognostic scoring system.
How Doctors Estimate Your Prognosis
Once all the diagnostic information is gathered, doctors calculate a risk score using the Follicular Lymphoma International Prognostic Index (FLIPI). This uses five straightforward clinical factors, each counting as one point: age over 60, Ann Arbor stage III or IV disease, hemoglobin below 12 g/dL, more than four involved lymph node areas, and an elevated LDH level. The total divides patients into three risk groups (low, intermediate, and high), which helps guide how aggressively treatment needs to begin and how closely you’ll be monitored.
The updated version, FLIPI-2, swaps out some of these factors and adds beta-2 microglobulin level, the size of the largest involved lymph node (whether it exceeds 6 cm), and whether the bone marrow is involved.
The Changing Role of Bone Marrow Biopsy
For years, a bone marrow biopsy was standard in the diagnostic workup. The majority of patients with advanced-stage follicular lymphoma have bone marrow involvement, and the biopsy was considered necessary for complete staging. Guidelines from both European and American oncology organizations endorsed it, particularly for confirming early-stage presentations or investigating unexplained low blood counts.
That recommendation has shifted. A large analysis found that bone marrow biopsy doesn’t change prognosis or treatment response assessment in 99% of patients with advanced-stage disease. Current expert opinion holds that it should no longer be routinely included for patients already known to have advanced-stage follicular lymphoma. It still plays a role for patients who appear to have early-stage disease and are being considered for localized radiation, since finding marrow involvement would change their treatment plan entirely.